Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib and Pembrolizumab in Resectable Clear Cell Renal Cell Carcinoma
NCT07691476Phase 2Not yet recruiting
- Sponsor
- Yonsei University
- Start
- Oct 2026
- Primary completion
- Oct 2028
01
Overview
A Phase 2 trial of zanzalintinib in clear cell renal cell carcinoma (ccRCC), sponsored by Yonsei University. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
zanzalintinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07691476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07691476.